Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA

FMCQF
Fresenius Medical Care AG & Co. KGaAUS flagOther OTC
43.82
USD
- -
- -
11.66BMarket Cap
Fresenius Medical Care AG & Co. KGaA
FMCQF
(Other OTC)

Recent

price

43.82

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
29.87
32.44
34.2
34.82
43.06
50.76
54.19
58.01
53.98
57.74
60.73
60.14
66.15
66.3
65.9
67.4
52.68
Revenue per Share
2.47
2.76
2.94
2.65
2.84
3.14
3.74
4.17
6.47
3.96
3.96
3.31
2.3
1.7
1.83
3.36
2.6
Basic EPS, GAAP
2.13
2.19
3.38
3.07
2.53
2.98
3.28
4.07
3.28
4.76
10.82
5.58
4.92
6.63
5.75
6.06
4.21
Free Cash Flow per Basic Share
0.59
0.72
0.67
0.71
0.86
0.78
0.8
0.96
1.06
1.17
1.19
1.34
1.35
1.12
1.19
1.45
- -
Dividend per Share
18.34
20.03
22.03
22.18
25.76
29.62
32.58
32.04
38.32
40.08
38.29
43.34
47.68
46.42
49.68
47.66
- -
Book Value per Share
-3.63
-5.01
-7.87
-7.64
-12.3
-11.91
-12.35
-9.68
-3.69
-11.68
-10.67
-10.66
-11.32
-8.15
-6.69
-5.43
- -
Tangible Book Value per Share
298
299
305
304
302
304
306
307
307
303
294
293
293
293
293
291
277
Basic Weighted Avg Shares
8,906
9,699
10,435
10,580
13,019
15,455
16,570
17,784
16,547
17,477
17,859
17,619
19,398
19,454
19,336
19,628
14,567
Sales/Revenue/Turnover
16.17
16.22
15.69
15.26
14.08
13.59
14.1
12.76
13.03
12.56
12.37
10.55
7.5
7.59
7.59
9.31
9.79
Operating Margin (%)
378
430
456
469
575
648
702
735
790
1,593
1,786
1,624
1,838
1,752
1,742
1,500
1,194
Depreciation Expense
736
826
897
804
860
955
1,144
1,280
1,982
1,200
1,164
969
673
499
538
978
719
Net Income, GAAP
35.18
33.8
31.32
32.04
31.66
31.82
30.58
22.18
18.67
21.83
25.85
22.45
26.65
29.1
29.9
21.22
20.06
Effective Tax Rate (%)
8.26
8.52
8.6
7.6
6.6
6.18
6.9
7.2
11.98
6.86
6.52
5.5
3.47
2.57
2.78
4.98
4.94
Profit Margin (%)
1,025
1,105
2,236
1,979
2,665
2,395
1,585
1,074
1,579
106
1,219
710
1,736
2,590
2,263
1,653
- -
Working Capital
3,240
4,240
5,930
5,610
7,413
7,183
6,833
5,795
5,046
10,525
10,683
10,735
11,176
10,489
9,761
8,598
- -
LT Debt
5,657
6,219
6,962
6,869
8,247
9,600
11,051
10,828
12,902
13,227
12,331
13,979
15,449
14,827
15,769
14,283
- -
Total Equity
10.61
9.8
8.92
8.24
8.53
8.45
8.75
9.36
9.03
7.19
6.28
5.49
3.78
3.73
3.79
5.49
8.94
Return on Invested Capital (%)
9.22
8.67
8.28
7.01
6.63
6.03
6.35
7.1
10.86
5.67
4.63
3.82
2.56
2.04
2.31
4.12
6.1
Return on Capital (%)
14.43
14.2
13.97
11.96
11.89
11.36
12.03
12.93
18.37
10.12
10.05
8.11
5.05
3.61
3.82
7.02
10.84
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,197
2,389
- -
LT Borrowings
5,692
5,741
- -
LT Finance Leases
2,906
2,899
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
279
270
270
Market Capitalization
11,061
10,345
10,679

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
7,898
8,108
- -
Cash, Cash Equivalents & STI
1,821
1,623
- -
Accounts Receivable, Net
3,161
3,582
- -
Inventories
2,141
2,303
- -
Total Current Liabilities
6,245
6,730
- -
Payables & Accruals
1,378
1,042
- -
ST Debt
2,197
2,389
- -
Deferred Revenue
114
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.48%
3.36%
-9.42%
Free Cash Flow
14.54%
-6.84%
4.67%
Net Income, GAAP
6.06%
3.3%
81.88%
Sales/Revenue/Turnover
2.53%
1.99%
1.51%
Total Cash Common Dividend
6.51%
4.58%
21.01%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,725
4,766
4,760
5,085
19,336
2025
4,881
4,792
4,885
5,070
19,628
2026
4,612
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.64
0.73
0.23
1.83
2025
0.52
0.77
- -
1.14
3.36
2026
0.43
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.19
2025
- -
- -
- -
- -
1.45
2026
- -
- -
- -
- -
- -
Business
Fresenius Medical Care AG & Co. KGaA operates as a premier global entity in the comprehensive management of kidney diseases. The company delivers vital dialysis care services and a broad spectrum of associated support to individuals across the world suffering from chronic kidney failure and acute kidney conditions. Its service offerings encompass in-center dialysis treatments provided through an extensive international network of approximately 3,700 outpatient clinics, alongside support for home dialysis, and specialized care rendered under contract to hospitals for both hospitalized patients and those requiring acute renal support. Beyond its care delivery, Fresenius Medical Care is a prominent developer, manufacturer, and distributor of a diverse array of dialysis products. This includes advanced hemodialysis machines, dialyzers, bloodlines, solutions, and concentrates, as well as peritoneal dialysis cyclers and related solutions. The company also produces renal pharmaceuticals and sophisticated systems for water treatment, alongside non-dialysis products such as therapeutic apheresis systems. These products are supplied directly to its own clinics, other dialysis providers, and hospitals. Reflecting a strategic evolution, the company unveiled its FME Reignite strategy in June 2025, which includes the introduction of Value-Based Care as a distinct operating segment. This segment focuses on enhancing patient outcomes and managing the full kidney care journey through holistic and outcome-driven care coordination programs. As of late 2024, the company was caring for over 299,000 patients globally. Fresenius Medical Care AG & Co. KGaA, established in 1996, maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.